Special Investigation in Japanese Rheumatoid Arthritis Patients Who Have no Previous Use of DMARDs and Biological Agents.
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2016
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 13 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Sep 2015.